HK1243646A1 - 用於调节骨密度的方法 - Google Patents

用於调节骨密度的方法 Download PDF

Info

Publication number
HK1243646A1
HK1243646A1 HK18103269.8A HK18103269A HK1243646A1 HK 1243646 A1 HK1243646 A1 HK 1243646A1 HK 18103269 A HK18103269 A HK 18103269A HK 1243646 A1 HK1243646 A1 HK 1243646A1
Authority
HK
Hong Kong
Prior art keywords
subject
compound
hydrogen
disease
months
Prior art date
Application number
HK18103269.8A
Other languages
English (en)
Chinese (zh)
Inventor
夏皮罗 大卫
夏皮羅 大衛
卢西亚诺 阿多里尼
盧西亞諾 阿多里尼
Original Assignee
英特塞普特医药品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英特塞普特医药品公司 filed Critical 英特塞普特医药品公司
Publication of HK1243646A1 publication Critical patent/HK1243646A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18103269.8A 2015-03-09 2016-03-08 用於调节骨密度的方法 HK1243646A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130144P 2015-03-09 2015-03-09
US62/130,144 2015-03-09
PCT/US2016/021344 WO2016144946A1 (en) 2015-03-09 2016-03-08 Methods for modulating bone density

Publications (1)

Publication Number Publication Date
HK1243646A1 true HK1243646A1 (zh) 2018-07-20

Family

ID=56879295

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103269.8A HK1243646A1 (zh) 2015-03-09 2016-03-08 用於调节骨密度的方法

Country Status (12)

Country Link
US (1) US20180042943A1 (enExample)
EP (1) EP3268009A4 (enExample)
JP (1) JP2018507880A (enExample)
KR (1) KR20170125927A (enExample)
CN (1) CN107530361A (enExample)
AU (1) AU2016229906A1 (enExample)
CA (1) CA2978916A1 (enExample)
HK (1) HK1243646A1 (enExample)
IL (1) IL254197A0 (enExample)
MX (1) MX2017011399A (enExample)
SG (1) SG11201707328SA (enExample)
WO (1) WO2016144946A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US10919162B2 (en) 2018-12-26 2021-02-16 Ford Global Technologies, Llc Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries
DE102020101118A1 (de) 2019-01-18 2020-07-23 Ford Global Technologies, Llc Mobile mehrzweckroboter und verfahren zu deren verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223214B2 (en) * 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
JP2012072095A (ja) * 2010-09-29 2012-04-12 Tokyo Institute Of Technology 骨形成促進剤
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
WO2014021694A1 (ko) * 2012-08-03 2014-02-06 서울대학교 산학협력단 골 관련 질환 예방 및 치료를 위한 조성물
HRP20180931T1 (hr) * 2013-05-14 2018-10-05 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x

Also Published As

Publication number Publication date
AU2016229906A1 (en) 2017-09-21
CA2978916A1 (en) 2016-09-15
US20180042943A1 (en) 2018-02-15
JP2018507880A (ja) 2018-03-22
WO2016144946A1 (en) 2016-09-15
SG11201707328SA (en) 2017-10-30
MX2017011399A (es) 2018-03-16
IL254197A0 (en) 2017-10-31
CN107530361A (zh) 2018-01-02
KR20170125927A (ko) 2017-11-15
EP3268009A4 (en) 2018-12-12
EP3268009A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
Benedek History of the development of corticosteroid therapy
AU2017223154B2 (en) Methods for using FXR agonists
EP3419625B1 (en) Methods for using fxr agonists
EP0906106B1 (en) Prevention and treatment of colonic adenoma or colonic microadenoma by 6-fluoroursodeoxycholic acid (6-fudca)
KR20180126574A (ko) 담즙울체성 질환의 치료 방법
CN113908158A (zh) 使用fxr激动剂的方法
HK1243646A1 (zh) 用於调节骨密度的方法
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
Mazzella et al. Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients: effects on biliary lipid metabolism during weight maintenance and weight reduction
WO2012061086A2 (en) Method of treating neuroendocrine tumors
CN112791077A (zh) 一种秋水仙碱复合制剂，用于肝病的治疗或促进疗效
US20170157080A1 (en) Methods and compositions for the treatment of diverticulosis
Hamdy Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
WO2019209840A1 (en) Methods and compositions for treating rheumatoid arthritis
CN106466326B (zh) 特女贞苷及其组合物和药物制剂在降脂中的应用
KR20080091824A (ko) 메글리티니드류를 함유하는 간 섬유화 예방용 의약 조성물
CN103599108B (zh) 齐墩果酸在制备预防和治疗胆汁淤积症药物中的应用
WO2012106947A1 (zh) 含维生素d和二甲双胍的药物组合物
Mulatero et al. PS-C37-5: NEW THERAPEUTIC PERSPECTIVES FOR BLOOD PRESSURE CONTROL: DEXFADROSTAT PHOSPHATE, A NOVEL ALDOSTERONE SYNTHASE INHIBITOR, IN PATIENTS WITH PRIMARY ALDOSTERONISM
CN119280227A (zh) 治疗与s1p1受体相关的病症的方法
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
Mayo Non-PBC, Non-PSC autoimmune cholangiopathy
TWI228992B (en) Treatment of subnormal bone mineral density
WO2025040345A1 (en) Elafibranor for use in the treatment of primary biliary cholangitis
CN118267476A (zh) 一种药物组合、药物组合物及其应用